Insider Trading July 2, 2026 05:30 PM

Calumet Director Daniel Sajkowski Executes Pre-Arranged Sale Amid Volatile Earnings Landscape

Executive offloads shares under Rule 10b5-1 plan as company navigates significant earnings miss and stock appreciation.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
CLMT

Daniel J. Sajkowski, a director at Calumet, Inc., executed a sale of 4,240 shares on July 1, 2026, realizing approximately $153,318. The transaction was conducted under a pre-arranged trading plan adopted in November 2025, when the stock traded significantly lower. This sale occurs against a backdrop of recent financial results where Calumet reported a substantial earnings miss, though revenue slightly beat estimates.

Calumet Director Daniel Sajkowski Executes Pre-Arranged Sale Amid Volatile Earnings Landscape
CLMT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Daniel Sajkowski sold 4,240 shares for $153,318 under a Rule 10b5-1 plan adopted when the stock was at $19.08.
  • Calumet reported a Q1 2026 EPS miss of -$3.64 against expectations of -$0.31, though revenue beat estimates at $1.03 billion.
  • The stock has surged 123% over the past year, trading near a 52-week high of $38.75, while analysis suggests it is overvalued relative to Fair Value.

Daniel J. Sajkowski, serving as a director at Calumet, Inc. (NASDAQ: CLMT), has completed a transaction involving the sale of 4,240 shares of the company's common stock. The execution of this sale took place on July 1, 2026, resulting in a total transaction value of $153,318.

The shares were sold at prices fluctuating between $35.72 and $36.33 per share. Calculating the weighted average across these transactions yields a sale price of $36.16 per share. This execution was carried out under the guidelines of a Rule 10b5-1 trading plan. Mr. Sajkowski established this pre-arranged plan on November 18, 2025.

At the time the trading plan was adopted, Calumet's common stock closed at $19.08 per share on the Nasdaq Global Select Market. Since that November date, the stock has experienced a significant appreciation, surging 123% over the past year according to InvestingPro data. The equity is currently trading near its 52-week high of $38.75.

Following the completion of these transactions, Mr. Sajkowski's direct ownership of Calumet, Inc. common stock stands at 77,718 shares. Market analysis from InvestingPro indicates that the stock is currently overvalued relative to its Fair Value estimate.

This insider activity coincides with recent financial reporting from Calumet Inc. The company reported financial results for the first quarter of 2026, which revealed a notable miss on earnings expectations. The reported earnings per share (EPS) stood at -$3.64. This figure was significantly below the anticipated EPS of -$0.31.

Despite the shortfall in earnings, Calumet's revenue performance slightly exceeded market forecasts. The company reported revenue of $1.03 billion, surpassing the forecasted $1.01 billion. These financial developments have generated reactions within the market, reflecting investor concerns regarding the company's financial performance. The divergence between earnings misses and revenue beats highlights challenges in aligning financial outcomes with market forecasts.

Risks

  • The significant earnings miss in Q1 2026 indicates potential challenges in aligning financial outcomes with market forecasts, impacting investor confidence.
  • Analyst data suggests the stock is overvalued relative to its Fair Value estimate, posing valuation risks for investors.
  • The divergence between revenue beats and earnings misses highlights operational or margin pressures that could affect future financial stability.

More from Insider Trading

Ormat Technologies Executive Divests Shares Amid Geothermal Expansion Jul 2, 2026 Exodus Movement Director Margaret Knight Disposes of 135 Shares Amidst Stock Volatility Jul 2, 2026 Kratos Defense Executive Stacey G. Rock Executes $233,750 Stock Sale Under Pre-Arranged Trading Plan Jul 2, 2026 Roku Director Neil Hunt Disposes of $281,306 in Shares via 10b5-1 Plan Jul 2, 2026 Nurix Therapeutics Executive Disposes of Equity Stake Under Pre-Arranged Plan Jul 2, 2026